Kronos Bio
We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
San Mateo, United States
70 employees
Private Equity
Total: $278.00M
Biotechnology, Health and Wellness
General Information
Get notified when Kronos Bio moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Kronos Bio
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Kronos Bio
Taxonomy: biopharmaceutical company, clinical-stage, therapeutics, CDK9 inhibitor, transcription factor, oncology, cancer treatment, myc-dependent tumors, transcriptional addiction, discovery collaboration, Genentech partnership, p300 KAT domain, multiple myeloma, transcriptional targets, precision medicine
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Private Equity Round | •••••• | 10 |
|
25 Aug 2020 |
| Series A | •••••• | - | 18 Jul 2019 | |
| Seed Round | •••••• | - | 05 Jun 2018 |
Kronos Bio Alternatives & Competitors
Red blood cells are no longer just for carrying oxygen. At Rubius Therapeutics, we are transforming...
Groundbreaking Cancer Therapies
Destroying some of the deadliest squamous cell cancers at their source.
FAQ About Kronos Bio
Don't just browse. Track.
Signal Tracker monitors Kronos Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.